- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01603823
Angiographie and OCT in Macula and Retinal Diseases
May 21, 2012 updated by: Stefan Sacu, Medical University of Vienna
The purpose of this study is to investigate the morphological and angiological retinal changes in different macular diseases.
Study Overview
Status
Completed
Conditions
Detailed Description
Recently, a new generation of OCT devices relying on spectral domain technology (SD-OCT) has been introduced and allows for higher-resolution imaging.
Based on this technology we can identify variable changes at the retinal surface such as, retinal thickening with cyst formation, swelling in the inner and outer nuclear layers and subretinal fluid.
The introduction of an eye-tracking mode has allowed a better insight into the development of retinal morphologic changes The aim of this study was to investigate the incidence and structural morphology of PCME after successful uncomplicated cataract surgery in patients with previous pars plana vitrectomy (PPV) and indocyanine green-assisted peeling of an epiretinal membrane and the internal limiting membrane (ILM).
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Twenty eyes of 20 patients with previous 23-gauge PPV and ILM peeling (PPV group) and 15 consecutive eyes with senile cataract with a healthy macula (control group) were included.
Description
Inclusion Criteria:
- previous 23-gauge PPV and ILM peeling
Exclusion Criteria:
- history of branch retinal vein occlusion
- central retinal vein occlusion
- wet macular degeneration
- diabetic retinopathy
- uveitis or other inflammatory eye disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Healthy volunteers
|
|
St.p. Pars plana vitrectomy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
February 1, 2010
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
May 19, 2012
First Submitted That Met QC Criteria
May 21, 2012
First Posted (Estimate)
May 22, 2012
Study Record Updates
Last Update Posted (Estimate)
May 22, 2012
Last Update Submitted That Met QC Criteria
May 21, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10082007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
Alexandria UniversityRecruitingDiabetic Macular Edema | Center-involved Diabetic Macular EdemaEgypt
-
Hoffmann-La RocheCompletedDiabetic Macular Edema | Uveitic Macular EdemaUnited States
-
Curacle Co., Ltd.Not yet recruitingDiabetic Macular Edema | Diabetic Macular Edema (DME) | DME
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
OcugenRecruitingDiabetic Macular Edema | Center Involved Diabetic Macular EdemaUnited States
-
EyePoint Pharmaceuticals, Inc.RecruitingDiabetic Macular Edema | Diabetic Macular Edema (DME) | DMEIsrael, United States, Poland, Germany, Slovakia
-
EyePoint Pharmaceuticals, Inc.RecruitingDiabetic Macular Edema | Diabetic Macular Edema (DME) | DMEUnited States, Hungary, Czechia, Brazil, Germany
-
Vitreo-Retinal Associates, MichiganVan Andel Research InstituteCompletedDiabetic Macular Edema | Exudative Macular DegenerationUnited States